Table 1.
Demographic and clinical parameters for the patients who received antifungal therapy.
Table 2.
Fungal agents isolated from oncohematological patients.
Table 3.
Available antifungal susceptibility of fungal isolates from patients with hematologic malignances.
Table 4.
Outcome of patients treated with antifungal drugs.
Fig 1.
Clinical characteristics, diagnostic procedures, EORTC/MSG classification, distribution of AFT and association with outcome.
(A) Proportion of patients undergoing or not undergoing to AFT. (B) Diagnoses among the group of patients undergoing AFT. (C) Distribution of neutropenia in the patients undergoing to AFT. (D) Proportion of lung CT scans positive and negative in the patients undergoing AFT. (E) Distribution of positive lung CT scan across the different diagnoses. (F) Distribution of GM and lung CT scan positivity/negativity. (G) EORTC/MSG classification of the AFT patients. (H) Distribution of neutropenia in the different EORTC/MSG classes. (I) Distribution of different antifungal agents among positive (alive) and negative (dead) outcomes.